The Journey Has Just Begun For LAG-3 Therapeutics
Executive Summary
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
You may also be interested in...
Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up
PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.
ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.